Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBT-10X is an engineered bacterial therapeutic being developed by CommBio Therapeutics for the treatment of colorectal cancer and conditions involving the brain-gut axis. As a live biotherapeutic product (LBP), it utilizes synthetic biology to modify bacteria to perform therapeutic functions within the gastrointestinal tract. The program is designed to leverage the microbiome's role in oncology and systemic signaling, potentially through the localized delivery of therapeutic payloads or the modulation of metabolic pathways. It is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CBT-10X.